211 related articles for article (PubMed ID: 26775931)
1. The Centers for Disease Control and Prevention definition of mucosal barrier injury-associated bloodstream infection improves accurate detection of preventable bacteremia rates at a pediatric cancer center in a low- to middle-income country.
Torres D; González ML; Loera A; Aguilera M; Relyea G; Aristizabal P; Caniza MA
Am J Infect Control; 2016 Apr; 44(4):432-7. PubMed ID: 26775931
[TBL] [Abstract][Full Text] [Related]
2. The burden of mucosal barrier injury laboratory-confirmed bloodstream infection among hematology, oncology, and stem cell transplant patients.
Metzger KE; Rucker Y; Callaghan M; Churchill M; Jovanovic BD; Zembower TR; Bolon MK
Infect Control Hosp Epidemiol; 2015 Feb; 36(2):119-24. PubMed ID: 25632993
[TBL] [Abstract][Full Text] [Related]
3. Mucosal barrier injury laboratory-confirmed bloodstream infection: results from a field test of a new National Healthcare Safety Network definition.
See I; Iwamoto M; Allen-Bridson K; Horan T; Magill SS; Thompson ND
Infect Control Hosp Epidemiol; 2013 Aug; 34(8):769-76. PubMed ID: 23838215
[TBL] [Abstract][Full Text] [Related]
4. Impact of mucosal barrier injury laboratory-confirmed bloodstream infection (MBI-LCBI) on central line-associated bloodstream infections (CLABSIs) in department of hematology at single university hospital in Japan.
Kato Y; Hagihara M; Kurumiya A; Takahashi T; Sakata M; Shibata Y; Kato H; Shiota A; Watanabe H; Asai N; Koizumi Y; Yamagishi Y; Mikamo H
J Infect Chemother; 2018 Jan; 24(1):31-35. PubMed ID: 29066217
[TBL] [Abstract][Full Text] [Related]
5. Mucosal Barrier Injury Laboratory-Confirmed Bloodstream Infections (MBI-LCBI): Descriptive Analysis of Data Reported to National Healthcare Safety Network (NHSN), 2013.
Epstein L; See I; Edwards JR; Magill SS; Thompson ND
Infect Control Hosp Epidemiol; 2016 Jan; 37(1):2-7. PubMed ID: 26456954
[TBL] [Abstract][Full Text] [Related]
6. Mucosal barrier injury-associated bloodstream infections in pediatric oncology patients.
Hakim H; Billett AL; Xu J; Tang L; Richardson T; Winkle C; Werner EJ; Hord JD; Bundy DG; Gaur AH;
Pediatr Blood Cancer; 2020 Aug; 67(8):e28234. PubMed ID: 32386095
[TBL] [Abstract][Full Text] [Related]
7. Healthcare Burden, Risk Factors, and Outcomes of Mucosal Barrier Injury Laboratory-Confirmed Bloodstream Infections after Stem Cell Transplantation.
Dandoy CE; Haslam D; Lane A; Jodele S; Demmel K; El-Bietar J; Flesch L; Myers KC; Pate A; Rotz S; Daniels P; Wallace G; Nelson A; Waters H; Connelly B; Davies SM
Biol Blood Marrow Transplant; 2016 Sep; 22(9):1671-1677. PubMed ID: 27311966
[TBL] [Abstract][Full Text] [Related]
8. A Prospective, Holistic, Multicenter Approach to Tracking and Understanding Bloodstream Infections in Pediatric Hematology-Oncology Patients.
Gaur AH; Bundy DG; Werner EJ; Hord JD; Miller MR; Tang L; Lawlor JP; Billett AL;
Infect Control Hosp Epidemiol; 2017 Jun; 38(6):690-696. PubMed ID: 28399945
[TBL] [Abstract][Full Text] [Related]
9. Impact of removing mucosal barrier injury laboratory-confirmed bloodstream infections from central line-associated bloodstream infection rates in the National Healthcare Safety Network, 2014.
See I; Soe MM; Epstein L; Edwards JR; Magill SS; Thompson ND
Am J Infect Control; 2017 Mar; 45(3):321-323. PubMed ID: 27856070
[TBL] [Abstract][Full Text] [Related]
10. Incidence, Risk Factors, and Outcomes of Patients Who Develop Mucosal Barrier Injury-Laboratory Confirmed Bloodstream Infections in the First 100 Days After Allogeneic Hematopoietic Stem Cell Transplant.
Dandoy CE; Kim S; Chen M; Ahn KW; Ardura MI; Brown V; Chhabra S; Diaz MA; Dvorak C; Farhadfar N; Flagg A; Ganguly S; Hale GA; Hashmi SK; Hematti P; Martino R; Nishihori T; Nusrat R; Olsson RF; Rotz SJ; Sung AD; Perales MA; Lindemans CA; Komanduri KV; Riches ML
JAMA Netw Open; 2020 Jan; 3(1):e1918668. PubMed ID: 31913492
[TBL] [Abstract][Full Text] [Related]
11. Central line-associated bloodstream infections in neonates with gastrointestinal conditions: developing a candidate definition for mucosal barrier injury bloodstream infections.
Coffin SE; Klieger SB; Duggan C; Huskins WC; Milstone AM; Potter-Bynoe G; Raphael B; Sandora TJ; Song X; Zerr DM; Lee GM;
Infect Control Hosp Epidemiol; 2014 Nov; 35(11):1391-9. PubMed ID: 25333434
[TBL] [Abstract][Full Text] [Related]
12. The applicability of the central line-associated bloodstream infection (CLABSI) criteria for the evaluation of bacteremia episodes in pediatric oncology patients.
van den Bosch CH; Frakking FNJ; Loeffen YGT; van Tinteren H; van der Steeg AFW; Wijnen MHWA; van de Wetering MD; van der Bruggen JT
Eur J Haematol; 2024 May; 112(5):832-839. PubMed ID: 38294085
[TBL] [Abstract][Full Text] [Related]
13. A clinical practical approach to the surveillance definition of central line-associated bloodstream infection in cancer patients with mucosal barrier injury.
Chaftari AM; Jordan M; Hachem R; Al Hamal Z; Jiang Y; Yousif A; Garoge K; Deshmukh P; Raad I
Am J Infect Control; 2016 Aug; 44(8):931-4. PubMed ID: 27112370
[TBL] [Abstract][Full Text] [Related]
14. Changes in Central Line-Associated Bloodstream Infection Rates Among Children With Immune Compromised Conditions: An 11-Year Review.
Linder LA; Gerdy C; Jo Y; Wilson A
J Pediatr Oncol Nurs; 2018; 35(6):382-391. PubMed ID: 29665727
[TBL] [Abstract][Full Text] [Related]
15. A Retrospective Analysis of Bloodstream Infections in Pediatric Allogeneic Stem Cell Transplant Recipients: The Role of Central Venous Catheters and Mucosal Barrier Injury.
Balian C; Garcia M; Ward J
J Pediatr Oncol Nurs; 2018 May; 35(3):210-217. PubMed ID: 29560765
[TBL] [Abstract][Full Text] [Related]
16. Impact of revising the National Nosocomial Infection Surveillance System definition for catheter-related bloodstream infection in ICU: reproducibility of the National Healthcare Safety Network case definition in an Australian cohort of infection control professionals.
Worth LJ; Brett J; Bull AL; McBryde ES; Russo PL; Richards MJ
Am J Infect Control; 2009 Oct; 37(8):643-8. PubMed ID: 19589619
[TBL] [Abstract][Full Text] [Related]
17. Prospective Initiative to Reduce Mucosal Barrier Injuries and Bloodstream Infections in Patients With Hematologic Malignancy Receiving Inpatient Chemotherapy.
Reed D; Sen J; Lassiter K; Thomas T; Harr E; Daniels E; Keng M
JCO Oncol Pract; 2020 Mar; 16(3):e306-e312. PubMed ID: 32048944
[TBL] [Abstract][Full Text] [Related]
18. Impact of a Best Practice Prevention Bundle on Central Line-associated Bloodstream Infection (CLABSI) Rates and Outcomes in Pediatric Hematology, Oncology, and Hematopoietic Cell Transplantation Patients in Inpatient and Ambulatory Settings.
Ardura MI; Bibart MJ; Mayer LC; Guinipero T; Stanek J; Olshefski RS; Auletta JJ
J Pediatr Hematol Oncol; 2021 Jan; 43(1):e64-e72. PubMed ID: 32960848
[TBL] [Abstract][Full Text] [Related]
19. Lessons learned from a hospital-wide review of blood stream infections for paediatric central line-associated blood stream infection prevention.
Campbell AJ; Blyth CC; Hewison CJ; Chen YP; Gough L; Goff Z; Bowen AC
J Paediatr Child Health; 2019 Jun; 55(6):690-694. PubMed ID: 30315622
[TBL] [Abstract][Full Text] [Related]
20. Distribution of pathogens in central line-associated bloodstream infections among patients with and without neutropenia following chemotherapy: evidence for a proposed modification to the current surveillance definition.
Steinberg JP; Robichaux C; Tejedor SC; Reyes MD; Jacob JT
Infect Control Hosp Epidemiol; 2013 Feb; 34(2):171-5. PubMed ID: 23295563
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
